Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma

Clinical Epigenetics

Table 1 The mutational landscape of PTCL

Mutational gene	Most frequent subtype	frequency	Frequent mutation in tumour type
TET2 [9, 10, 14, 116]	AITL, PTCL-NOS	42-89%, 28-48, 5%	MPN (~13%), (CMML) (~50%), MDS (25%), AML(~23%) [154]
DNMT3A [10, 14]	AITL, PTCL-NOS	25-33%, 27%	AMLs (20–30%), MDS (10–15%) [155]
IDH2	AITL [11] PTCL-NOS	20-45%, 7.5%156	AML(8–19%) [157] MDS (~5%) [158]
KMT2D/MLL2 [12, 58, 93]	All PTCL, AITL, PTCL-NOS	42%, 25%, 36%	DLBCL (35–85%) [159] FL (89%) [160]
KMT2C, SETD1B	PTCL, NOS [93, 156]	8.2%, 5.2%	Breast [161] cancer 8%MLL2+MLL3(16-20%) medulloblastoma [162, 163]
SETD2	EATL MEITL	32%, [83] 21/23 (91%) [84]	Renal cell carcinoma (13-30%) [164]

TET: ten eleven translocation protein, 2HG:2-hydroxyglutarate, IDH2: isocitrate dehydrogenase2, 5hmC: 5-hydroxymethylcytosine, EZH2: enhancer of zeste 2, MDS: myelodysplastic syndromes, AML: acute myeloid leukaemia

ISSN: 1868-7083